文献速递肝病

Miricorilant治疗拟诊MASH的1b期研究

Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
PubMed 文献 · Hepatology · 2026-10-26

这项1b期研究纳入70例拟诊MASH患者,接受口服miricorilant每日或间歇给药12或24周,各方案肝脏脂肪含量相对降幅10.1%至76.6%。间歇100 mg每周两次方案获益风险最佳,第12周LFC平均下降28.2%,ALT降3.8 U/L、AST降6.0 U/L。

要点

  • 间歇100 mg每周两次方案第12周LFC平均降28.2%,ALT降3.8 U/L、AST降6.0 U/L。
  • 每日给药者氨基转移酶升高多发生于LFC快速下降时,间歇给药完成12周比例更高。
  • 该方案正于2b期MONARCH研究(NCT06108219)中进一步评估。

核心结论

  • 间歇给予miricorilant 100 mg每周两次可实现有意义的LFC下降并改善肝脏健康标志物,安全性良好。

研究设计与样本

  • 1b期研究纳入70例拟诊MASH患者,口服miricorilant每日30-150 mg或间歇100-200 mg每周一次、两次或三次,疗程12或24周。

主要发现

  • 各给药方案肝脏脂肪含量相对降幅范围为10.1%至76.6%。
  • 各方案均观察到MASH肝功能标志物及增强肝纤维化(ELF)评分改善。
  • 导致中断或停药的治疗中出现的不良事件(TEAE)各占12.9%(n=9),多因LFC下降过快时氨基转移酶升高(第6周最高达70.2%)且多见于每日给药者。
  • 间歇给药使更多患者完成12周治疗且未因TEAE停药。
  • 间歇100 mg每周两次队列第12周LFC平均降28.2%,ALT降3.8 U/L、AST降6.0 U/L,血脂、血糖标志物及纤维化生物标志物呈数值改善。

临床怎么用

  • 间歇100 mg每周两次方案获益风险最佳,可作为后续2b期MONARCH研究(NCT06108219)的评估方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Miricorilant, an oral nonsteroidal selective glucocorticoid receptor modulator, is being investigated as a therapy that modulates hepatic cortisol activity in patients with metabolic dysfunction-associated steatohepatitis (MASH). This phase 1b study evaluated miricorilant's efficacy and safety. APPROACH AND RESULTS: Seventy patients with presumed MASH received oral miricorilant daily (30-150 mg) or intermittent (100-200 mg once, twice, or thrice weekly) dosing regimens for 12 or 24 weeks. Across dosing regimens, reductions in relative liver fat content (LFC) ranged from 10.1% to 76.6%. Improvements in MASH liver function markers and the enhanced liver fibrosis (ELF) score were observed across regimens. Treatment-emergent adverse events (TEAE) leading to drug interruption/discontinuation occurred in 12.9% of patients (n=9) each; most were due to aminotransferase elevations during an excessively rapid drop in LFC (up to 70.2% at week 6) and in patients receiving daily dosing. Intermittent dosing enabled more patients to complete 12 weeks of treatment without discontinuation due to TEAEs. Intermittent dosing with miricorilant 100 mg twice weekly had the best benefit-risk profile; this cohort demonstrated a mean LFC reduction of 28.2% at week 12, with a corresponding decline in liver enzymes (ALT, -3.8 U/L; AST, -6.0 U/L). Patients in this cohort also had numerical improvement in lipid profiles, glycemic markers, and fibrosis biomarkers. CONCLUSIONS: Intermittent miricorilant dosing of 100 mg twice weekly achieved meaningful reductions in LFC and improved liver health markers with a favorable safety profile. This regimen is being evaluated in the phase 2b MONARCH study (NCT06108219).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Alkhouri N, Rudraraju M, Leibowitz M, et al. Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). Hepatology. 2026. PMID: 42929711. doi:10.1097/HEP.0000000000001886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。